HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · IEX Real-Time Price · USD
18.16
-0.83 (-4.37%)
At close: Apr 26, 2024, 4:00 PM
18.24
+0.08 (0.44%)
After-hours: Apr 26, 2024, 7:55 PM EDT
HUTCHMED (China) Revenue
In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$838.00M
Revenue Growth
+135.31%
P/S Ratio
3.78
Revenue / Employee
$421,529
Employees
1,988
Market Cap
3.16B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
Dec 31, 2014 | 87.33M | 50.78M | 138.95% |
Dec 31, 2013 | 36.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 3.11B |
Envista Holdings | 2.57B |
Evolent Health | 1.96B |
iRhythm Technologies | 492.68M |
Axonics | 366.38M |
Axsome Therapeutics | 270.60M |
SpringWorks Therapeutics | 5.45M |
Crinetics Pharmaceuticals | 4.01M |
HCM News
- 1 day ago - HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - GlobeNewsWire
- 22 days ago - HUTCHMED Highlights Data to be Presented at AACR Congress 2024 - GlobeNewsWire
- 25 days ago - Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status - PRNewsWire
- 25 days ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status - GlobeNewsWire
- 4 weeks ago - HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - GlobeNewsWire
- 5 weeks ago - HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 2 months ago - HUTCHMED Reports 2023 Full Year Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session - GlobeNewsWire